Sourasky Medical Center (Ichilov)
| イスラエル | トルコ | オーストリア | |
| 乳癌化学療法 | から $22,500 | から $1,200 | から $15,000 |
| ガンマナイフ | から $13,800 | から $6,300 | から $32,000 |
| 放射線療法 | - | から $3,250 | から $18,000 |
| 大腸癌に対する放射線療法 | - | から $7,000 | から $12,000 |
メリムスキー教授は、スーラスキー医療センターの軟部組織・骨腫瘍科を統括し、1995年より肉腫診療を専門としています。
Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.
He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.
He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.
この医師は小児血液学および腫瘍学の分野での第一人者であり、特に小児の血液疾患および骨癌（肉腫）に特化しています。現在、この医師はテルアビブのSourasky Medical Centerの小児血液腫瘍科のディレクターを務め、Dana Children's Hospitalの上級小児科医でもあります。この医師は骨癌および軟部組織肉腫の治療を調整し、血液凝固障害を管理し、早産児の血液学を監督しています。この医師はイスラエル小児血液腫瘍学会（ISPHO）のメンバーです。
この医師はベングリオン大学を卒業し、Kaplan Medical Centerで小児医学を専門とし、Schneider Children's Medical Centerで小児血液学および腫瘍学をさらに専門としました。追加のトレーニングはイタリアのRizzoli Orthopaedic Instituteで骨および軟部組織の腫瘍学において完了しました。
この医師は、骨肉腫、滑膜肉腫、骨癌の転移、ユーイング肉腫、横紋筋肉腫、骨癌、平滑筋肉腫を含む様々な種類の肉腫の治療を専門としています。この医師は、軍事医学および外科腫瘍学への貢献に対して、Tannenbaum Grant for Excellence in Surgical Oncology や Navigated Sarcoma Surgery Guided Therapeutics GTx Stroble Grant を含む複数の賞を受賞しています。
この医師は、American Musculoskeletal Tumor Society、Connective Tissue Oncology Society、および International Society of Limb Salvage のメンバーです。教育には、Ben-Gurion Medical School での訓練と、整形外科腫瘍学および関節形成術の専門フェローシップが含まれます。
Osteosarcoma treatment in Israel follows a rigorous three-stage protocol involving neoadjuvant chemotherapy, limb-sparing surgical resection, and adjuvant chemotherapy. Specialist centers like Sourasky Medical Center and Sheba Medical Center prioritize tumor shrinkage with aggressive drug regimens. This approach enables a 95% success rate for limb-salvage procedures.
Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center offer highly specialized pediatric-specific protocols that are not available at every general hospital. For example, their allogeneic bone marrow transplant package for pediatric osteosarcoma includes a 30-day hospital stay. This level of intensive inpatient monitoring is a critical differentiator for high-risk childhood cases compared to standard outpatient chemo cycles.
Patient Consensus: Patients note that the recovery phase after limb-salvage surgery is physically demanding. They emphasize the importance of requesting a fertility preservation consultation before starting the first round of aggressive chemotherapy.
Israeli surgeons perform limb-preserving surgery for 90% to 95% of osteosarcoma cases. These procedures prioritize tumor removal while maintaining functional use of the arm or leg. Specialists integrate 3D-modeled implants and navigation-guided resections. This approach successfully replaces amputation as the primary treatment standard.
Bookimed Expert Insight: Israeli orthopedic oncology units, like the one at Sourasky Medical Center active since 1995, manage massive patient volumes exceeding 1.8 million annually. This high frequency allows centers to maintain unique sub-specialties specifically for pediatric bone tumors. For example, Dr. Dror Levin combines oncology with specialized training from Italy’s Rizzoli Institute. Such concentrated expertise is rare and ensures that even complex cases in growing children benefit from the most specialized limb-salvage protocols available globally.
Patient Consensus: Patients note it is important to choose centers that provide multidisciplinary teams, specifically highlighting how orthopedic and plastic surgeons work together. Many mention the relief of avoiding repeated surgeries for children thanks to the remotely adjustable growing implants.
Advanced systemic therapies for metastatic or relapsed osteosarcoma in Israel focus on personalized immunotherapy and targeted drug protocols. Leading facilities like Sheba Medical Center and Sourasky Medical Center provide CAR-T cell therapy, tumor-infiltrating lymphocytes (TIL), and precision tyrosine kinase inhibitors. These treatments aim to stabilize disease and improve survival.
Bookimed Expert Insight: Israeli oncology centers like Sourasky report a 90% success rate in general oncology treatments. This is driven by deep specialization in rare subtypes. For example, Dr. Ofer Merimsky has over 40 years of experience specifically in sarcomas. Clinicians here often lead clinical trials for targeted drugs like Lenvatinib before they become global standards. This provides patients with access to therapies that are not yet available in many other countries.
Patient Consensus: Patients emphasize the importance of requesting Next-Generation Sequencing (NGS) tumor profiling early to identify targeted drug options. Families note that compassionate use programs at hospitals like Sheba can provide access to experimental combinations when standard chemotherapy fails.
Israel hosts globally recognized bone sarcoma centers including Sheba Medical Center, Sourasky Medical Center, and Rambam Health Care Campus. Most facilities hold JCI accreditation and rank among Newsweek’s top medical institutions. These centers specialize in limb-salvage surgery and innovative targeted immunotherapies for osteosarcoma.
Bookimed Expert Insight: While many search for general oncology, the most successful outcomes in Israel occur at centers with dedicated orthopedic oncology units. For example, Sourasky Medical Center has a specialized Head of Metastatic Bone Lesions, Dr. Jakov Bikels. This granular specialization ensures that complex reconstructive surgeries happen alongside tumor removal rather than as a secondary concern.
Patient Consensus: Patients note that the professionalism and expertise of doctors like Dr. Dror Levin provide a pleasant experience. They recommend confirming if an integrated protocol including pathology and limb-salvage surgery is available before traveling.
Limb-salvage surgery in Israel typically requires a 7 to 10 day hospital stay. Patients often stand within 2 to 3 days using assistive devices. Specialized inpatient rehabilitation usually lasts 10 days. Full functional recovery for osteosarcoma patients may extend from 6 months to 1 year.
Bookimed Expert Insight: Israeli oncology centers like Sourasky or Sheba often integrate orthopedic surgeons directly into oncology teams. This allows patients to bypass local specialized rehab wait times. By choosing a facility with an onsite rehabilitation department, you can consolidate surgical follow-ups and intensive therapy in one city. This frequently shortens the non-weight-bearing phase by 1 to 2 months compared to fragmented care models.
Patient Consensus: Patients emphasize that rehabilitation is a long process requiring persistence and 3 weekly sessions. Many note that preparing for a 9 month non-weight-bearing period is helpful for mental and logistical readiness.